🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

642 results for “Pharma Mar S.A.” Clear

  1. MT-7117 Formulation Code C

    Pharma Mar S.A.

    Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

    phase 3 small molecule active

    1 trial

  2. MT-7117 Formulation Code C, MT-7117 Placebo

    Pharma Mar S.A.

    Erythropoietic Protoporphyria or X-Linked Protoporphyria

    phase 3 small molecule active

    1 trial

  3. MaaT013

    Pharma Mar S.A.

    Treatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.

    phase 3 small molecule active

    1 trial

  4. MomeGalen 1 mg/g cutaneous emulsion, Placebo to 0.1% mometasone furoate cutaneous emulsion (active ingredient-free vehicle of mometasone cutaneous emulsion), ECURAL Fettcreme, 1 mg/g Creme

    Pharma Mar S.A.

    Plaque psoriasis

    phase 3 small molecule active

    1 trial

  5. Monofer, injektions- og infusionsvæske, opløsning

    Pharma Mar S.A.

    Chronic Heart Failure

    phase 3 small molecule active

    1 trial

  6. NORADRENALINA TARTRATO MONICO 2 mg/ml Concentrato per soluzione per infusione

    Pharma Mar S.A.

    criticall illness

    phase 3 small molecule active

    1 trial

  7. Nacubactam, Imipenem/Cilastatin Kabi 500 mg/500 mg Pulver zur Herstellung einer Infusionslösung, Cefepim PANPHARMA 2 g Pulver zur Herstellung einer Injektions- bzw. Infusionslösung, AZACTAM 1 g, poudre et solution pour usage parentéral

    Pharma Mar S.A.

    Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP)

    phase 3 small molecule active

    1 trial

  8. OCA 5MG IR +BZF 400 MG SR

    Pharma Mar S.A.

    Primary Biliary Cholangitis (PBC)

    phase 3 small molecule active

    1 trial

  9. OCA IR 0.1 mg, 0,1 mg and 1,5 mg Placebo tablets, OCA 1.5 mg

    Pharma Mar S.A.

    Biliary Atresia, Post-hepatoportoenterostomy

    phase 3 small molecule active

    1 trial

  10. OPDIVO 10 mg/mL concentrate for solution for infusion., TIVOZANIB, TIVOZANIB

    Pharma Mar S.A.

    Renal cell carcinoma

    phase 3 small molecule active

    1 trial

  11. Octaplex 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Octaplex 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung

    Pharma Mar S.A.

    Acute major bleeding in patients receiving DOAC therapy with factor Xa inhibitor

    phase 3 small molecule active

    1 trial

  12. PARACETAMOL , Dapirolizumab pegol, Placebo matching dapirolizumab pegol and without active substance, -, DIPHENHYDRAMINE , -, EPINEPHRINE , -, -

    Pharma Mar S.A.

    Systemic lupus erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  13. PEMBROLIZUMAB , Adagloxad simolenin with adjuvant, CAPECITABINE

    Pharma Mar S.A.

    Triple Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  14. PL1 - Lyophilisate and solvent for solution for injection, sotatercept

    Pharma Mar S.A.

    Pulmonary Arterial Hypertension (PAH)

    phase 3 small molecule active

    1 trial

  15. PREDNISOLONE , Dupixent 300 mg solution for injection in pre-filled syringe, Placebo matching to dupilumab

    Pharma Mar S.A.

    Bullous Pemphigoid

    phase 3 small molecule active

    1 trial

  16. Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Armisarte 25 mg/ml concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, LIBTAYO 350 mg concentrate for solution for infusion.

    Pharma Mar S.A.

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  17. Paracetamol/Ibuprofen Vale 1000 mg/300 mg oldatos infúzió

    Pharma Mar S.A.

    Acute pain

    phase 3 small molecule active

    1 trial

  18. Placebo (Lisaftoclax), Lisaftoclax, Azacitidine Seacross 25 mg/mL powder for suspension for injection

    Pharma Mar S.A.

    Newly Diagnosed Higher Risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  19. Placebo for ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion

    Pharma Mar S.A.

    complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)

    phase 3 small molecule active

    1 trial

  20. Placebo for Acetylsalicylic Acid, ACETYLSALICYLIC ACID, REGN7508, Placebo for REGN7508

    Pharma Mar S.A.

    Symptomatic Venous Thromboembolism (VTE)

    phase 3 small molecule active

    1 trial

  21. Placebo for Mitapivat, MITAPIVAT

    Pharma Mar S.A.

    Non–Transfusion-Dependent Alpha- or Beta-Thalassemia

    phase 3 small molecule active

    1 trial

  22. Placebo for cemdisiran is 0.9% saline and will be supplied by the sponsor., Pozelimab, Placebo for pozelimab will be provided in an aqueous buffered solution and supplied by the sponsor., Cemdisiran

    Pharma Mar S.A.

    Geographic Atrophy Secondary to Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  23. Placebo liquid formulation will be indistinguishable from its tasimelteon counterpart and will be administered in the same way., Tasimelteon

    Pharma Mar S.A.

    Insomnia Disorder

    phase 3 small molecule active

    1 trial

  24. Placebo matching < Staccato® alprazolam > and without active substance, alprazolam

    Pharma Mar S.A.

    Stereotypical prolonged seizure

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources